<p>Tepkinly is a cancer medicine used to treat adults with blood cancers called diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), in patients whose cancer has returned (relapsed) or stopped responding (refractory) after at least two previous treatments.</p><p>Tepkinly contains the active substance epcoritamab.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.<br><br>Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.<br><br>Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.<br><br>Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. </p></div>
Therapeutic Area (MeSH)
ATC Code
L01FX27
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| epcoritamab | N/A | epcoritamab |
EMA Name
Tepkinly
Medicine Name
Tepkinly
Aliases
N/ANo risk management plan link.
